Lithium: the pharmacodynamic actions of the amazing ion
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Lithium has been used for the treatment of mood disorders for over 60 years, yet the exact mechanisms by which it exerts its therapeutic effects remain unclear. Two enzymatic chains or pathways emerge as targets for lithium: inositol monophosphatase within the phosphatidylinositol signalling pathway and the protein kinase glycogen synthase kinase 3. Lithium inhibits these enzymes through displacing the normal cofactor magnesium, a vital regulator of numerous signalling pathways. Here we provide an overview of evidence, supporting a role for the inhibition of glycogen synthase kinase 3 and inositol monophosphatase in the pharmacodynamic actions of lithium. We also explore how inhibition of these enzymes by lithium can lead to downstream effects of clinical relevance, both for mood disorders and neurodegenerative diseases. Establishing a better understanding of lithium’s mechanisms of action may allow the development of more effective and more tolerable pharmacological agents for the treatment of a range of mental illnesses, and provide clearer insight into the pathophysiology of such disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in healthcare, many drugs for which the mechanism of action is unknown are trusted due to years of use that illustrate high efficacy and a clean safety profile (e.g., lithium14).”
From Machine intelligence in healthcare—perspectives on trustworthiness, explainability, usability, and transparency (2020) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244 · cited 10×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialInositol phosphates and cell signalling
Berridge, M. J., & Irvine, R. F. (1989) · Nature · doi:10.1038/341197a0 · Cited by 4,058
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301 · cited 6×
“Direct and indirect inhibition of GSK3 by lithium In 1996, two independent studies demonstrated lithium’s effects as a direct inhibitor of GSK3 in vitro and in cells [Klein and Melton, 1996; Stambolic et al. 1996].”
BackgroundInfluentialGSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 2×
“2006] and is primarily regulated through inhibition of its activity via a combination of factors [Kaidanovick-Beilin and Woodgett, 2011], including phosphorylation, intracellular localisation and sequestration by binding proteins [Doble and Woodgett, 2003; Jope and Johnson, 2004; Kockeritz et al. 2006].”
BackgroundThe glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517 · cited 2×
“2006] and is primarily regulated through inhibition of its activity via a combination of factors [Kaidanovick-Beilin and Woodgett, 2011], including phosphorylation, intracellular localisation and sequestration by binding proteins [Doble and Woodgett, 2003; Jope and Johnson, 2004; Kockeritz et al. 2006].”
BackgroundCohen, P., & Frame, S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096075 · Cited by 1,478 · cited 2×
“…2010], and has a key role in the regulation of a number of cell functions, including insulin receptor signalling, the specification of cell fates during embryonic development, immunity and inflammation responses and neurotransmission [Cohen and Frame, 2001; KaidanovichBeilin and Woodgett, 2011].”
BackgroundLITHIUM SALTS IN THE TREATMENT OF PSYCHOTIC EXCITEMENT
Cade, J. F. J. (1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb36912.x · Cited by 1,463
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410 · cited 2×
“Activation of Akt involves phosphorylation of a regulatory threonine residue (Thr 308) by phosphatidylinositol-dependent kinase 1 (PDK1) and additional phosphorylation of the Ser 473 residue by the PDK2/TORC2 kinase [Alessi and Cohen, 1998; Jacinto et al. 2006], in response to phosphatidylinositol kinase (PI3K)-mediat…”
BackgroundMethodLithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 6×
“…lymphoma/leukaemia 2 (bcl-2) [Chen et al. 1999; Manji et al. 2000a; Moore et al. 2000b], as well as its effects on GSK3 [Klein and Melton, 1996; Stambolic et al. 1996; Chalecka-Franaszek and Chuang, 1999; De Sarno et al. 2002; Beaulieu et al. 2004], is thought to exert major neurotrophic…”
BackgroundInfluentialLithium salts in the treatment of psychotic excitement
Cade, J. F. J. (1999) · Australian and New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.1999.06241.x · Cited by 1,150
Hallcher, L. M., & Sherman, W. R. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70391-3 · Cited by 1,101 · cited 1×
“Myoinositol is a prominent form of the six-carbon sugar inositol, and an essential component of the PI intracellular signalling pathway [Hallcher and Sherman, 1980].”
BackgroundNeural and developmental actions of lithium: A unifying hypothesis
Berridge, M. J., Downes, C. P., & Hanley, M. R. (1989) · Cell · doi:10.1016/0092-8674(89)90026-3 · Cited by 1,014 · cited 7×
“…phosphate metabolism, including the intracellular enzymes IMPase and inositol polyphosphatase 1-phosphatase (IPP 1) [Allison and Stewart, 1971; Berridge et al. 1989; Phiel and Klein, 2001]; this inhibition leads to inositol depletion, a consequential reduction in the resynthesis…”
BackgroundInfluentialLithium induces autophagy by inhibiting inositol monophosphatase
Sarkar, S., Floto, R. A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., Cook, L. J., & Rubinsztein, D. C. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504035 · Cited by 985 · cited 4×
“Induction of autophagy Autophagy is a physiological process for the bulk degradation of cytoplasmic proteins or organelles [Sarkar et al. 2005] and an important regulator of cellular (including neuronal) survival and function [Chiu and Chuang, 2010].”
BackgroundInfluentialAn Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior
Beaulieu, J.-M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R., & Caron, M. G. (2005) · Cell · doi:10.1016/j.cell.2005.05.012 · Cited by 980
Sutherland, C., Leighton, I. A., & Cohen, P. (1993) · Biochemical Journal · doi:10.1042/bj2960015 · Cited by 903 · cited 10×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluential(2008) · Cited by 889
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881 · cited 1×
“Altered autophagy could provide cognitive [Caccamo et al. 2010], neuroprotective [Chiu and Chuang 2010] and mood stabilisation [Cleary et al. 2008].”
BackgroundLithium toxicity profile: a systematic review and meta-analysis
McKnight, R. F., Adida, M., Budge, K., Stockton, S., Goodwin, G. M., & Geddes, J. R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61516-x · Cited by 877 · cited 2×
“In addition, lithium’s usage is limited by its narrow therapeutic window and significant range of adverse side effects [Livingstone and Rampes, 2006; McKnight et al. 2012]; better understanding its mechanism of action may allow the development of more effective and more tolerable pharmacological…”
BackgroundPhosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R., & Mills, G. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220413597 · Cited by 830 · cited 3×
“The phosphorylation state of this site is dynamic [Kaidanovich-Beilin and Woodgett, 2011] and regulated by a variety of kinases, including protein kinase B (Akt) [Cross et al. 1995], cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) [Fang et al. 2000] and PKC [Fang et al. 2002], although activatio…”
BackgroundMethodMania-like behavior induced by disruption of CLOCK
Roybal, K., Theobold, D., Graham, A., DiNieri, J. A., Russo, S. J., Krishnan, V., Chakravarty, S., Peevey, J., Oehrlein, N., Birnbaum, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609625104 · Cited by 803 · cited 2×
“Clock-mutant mice have been shown to display ‘manic’ behaviours that is reversed by the administration of lithium [Roybal et al. 2007] posited to be GSK3 inhibition, although lithium has also been noted to affect the free firing rate of mouse suprachiasmatic nucleus neurons [Abe et al. 2000; Li et…”
BackgroundBeaulieu, J.-M., Sotnikova, T. D., Yao, W.-D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., & Caron, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307921101 · Cited by 793 · cited 7×
“Lithium treatment can acutely affect this postsynaptic DA function by interfering with the effect of DA on the Akt/ GSK3 signalling cascade [Beaulieu et al. 2004].”
BackgroundInfluentialMechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743 · cited 2×
“Activation of Akt involves phosphorylation of a regulatory threonine residue (Thr 308) by phosphatidylinositol-dependent kinase 1 (PDK1) and additional phosphorylation of the Ser 473 residue by the PDK2/TORC2 kinase [Alessi and Cohen, 1998; Jacinto et al. 2006], in response to phosphatidylinositol kinase (PI3K)-mediat…”
MethodLTP Inhibits LTD in the Hippocampus via Regulation of GSK3β
Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.029 · Cited by 695 · cited 4×
“com 171 GSK3 inhibition may preserve and enhance both LTP and LTD [Peineau et al. 2007], with potential effects on learning and memory, which can be adversely affected in affective disorders, as well as neurodegenerative disorders.”
BackgroundInfluentialGeddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.217 · Cited by 661 · cited 1×
“…bipolar affective disorder, with evidence supporting its role in both acute mania [Gershon and Soares, 1997; Soares and Gershon, 1998, 2000; Bowden, 2000; Poolsup et al. 2000; Shafti, 2010] and prophylactic treatment [Soares and Gershon, 1998, 2000; Burgess et al. 2001; Geddes et al. 2004, 2010].”
BackgroundLithium-induced increase in human brain grey matter
Moore, G. J., Bebchuk, J. M., Wilds, I. B., Chen, G., & Menji, H. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02793-8 · Cited by 649 · cited 4×
“The regional specificity of these findings makes it unlikely that these findings are due to the osmotic effects of lithium; instead, the neurotrophic effect of lithium seems a more viable explanation [Moore et al. 2000b; Sassi et al. 2002; Bearden et al. 2007; Monkul et al. 2007].”
BackgroundInfluentialModulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation.
Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F., & Woodgett, J. R. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05715.x · Cited by 629 · cited 8×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialCipriani, A., Pretty, H., Hawton, K., & Geddes, J. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1805 · Cited by 617 · cited 2×
“2011], reduce suicide rates in affective disorders [Tondo and Baldessarini, 2000; Cipriani et al. 2005] and, more speculatively, has been considered as a possible therapeutic agent for treating chronic neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases [Marmol, 2008; Dudev and Lim, 2…”
BackgroundMitogen inactivation of glycogen synthase kinase-3 β in intact cells via serine 9 phosphorylation
Stambolic, V, & Woodgett, J. R. (1994) · Biochemical Journal · doi:10.1042/bj3030701 · Cited by 581 · cited 10×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialLithium toxicity profi le: a systematic review and meta-analysis
McKnight, R. F., Budge, K., Ba, S., Goodwin, G. M., Geddes, J. R., & Adida, M. (2012) · Cited by 544
Chalecka-Franaszek, E., & Chuang, D.-M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8745 · Cited by 542 · cited 4×
“2003] or because of increased activity of PKC and Akt activation [Chalecka-Franaszek and Chuang, 1999; De Sarno et al. 2002].”
BackgroundInfluentialAkt/GSK3 Signaling in the Action of Psychotropic Drugs
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145634 · Cited by 522 · cited 4×
“com activation leads to formation of an intracellular complex of β-arrestin2, Akt and protein phosphatase 2A (PP2A) that deactivates the Akt and subsequently stimulates GSK3 signalling, as well as accumulation of β-arrestins that both terminate the signalling and internalise the receptor complex [Beaulieu et al. 2009].”
BackgroundInfluentialMolecular Targets of Lithium Action
Phiel, C. J., & Klein, P. S. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.789 · Cited by 515 · cited 18×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialA Role for the Segment Polarity Gene shaggy/GSK-3 in the Drosophila Circadian Clock
Martinek, S., Inonog, S., Manoukian, A. S., & Young, M. W. (2001) · Cell · doi:10.1016/s0092-8674(01)00383-x · Cited by 514 · cited 1×
“In addition, lithium’s usage is limited by its narrow therapeutic window and significant range of adverse side effects [Livingstone and Rampes, 2006; McKnight et al. 2012]; better understanding its mechanism of action may allow the development of more effective and more tolerable pharmacological…”
BackgroundLithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes
Jope, R. S. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00206-2 · Cited by 500 · cited 2×
“Yet, despite lithium’s extensive clinical applications and its ability to provide potentially lifesaving treatment to patients [Nemeroff, 2000; Jope, 2003], the exact mechanisms by which it exerts its therapeutic effects remain incompletely understood [Phiel and Klein, 2001; Gould and Manji, 2005;…”
BackgroundChen, G., Zeng, W., Yuan, P., Huang, L., Jiang, Y., Zhao, Z., & Manji, H. K. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.720879.x · Cited by 494 · cited 2×
“Notably, lithium’s ability to robustly increase expression of the cytoprotective protein B-cell lymphoma/leukaemia 2 (bcl-2) [Chen et al. 1999; Manji et al. 2000a; Moore et al. 2000b], as well as its effects on GSK3 [Klein and Melton, 1996; Stambolic et al. 1996; Chalecka-Franaszek and Chuang,…”
BackgroundLithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium
Ryves, W. J., & Harwood, A. J. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4169 · Cited by 493 · cited 12×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialGSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485 · cited 2×
“The phosphorylation state of this site is dynamic [Kaidanovich-Beilin and Woodgett, 2011] and regulated by a variety of kinases, including protein kinase B (Akt) [Cross et al.”
BackgroundLithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3
Hong, M., Chen, D. C. R., Klein, P. S., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25326 · Cited by 469 · cited 6×
“2004] decreases the phosphorylation of tau protein and of MAP-1B [Hong et al. 1997; Munoz-Montano et al. 1997; Lovestone et al. 1999; Engel et al. 2006; Leroy et al. 2010], reducing their ability to bind to microtubules, leading to the promotion of microtubule assembly [Hong et al.”
BackgroundInfluentialInhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium
Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212635200 · Cited by 435 · cited 3×
“…of N-terminal serine residues of GSK3 [Chiu and Chuang, 2010; Pasquali et al. 2010], either due to inhibition of the protein phosphatases [Mora et al. 2002; Zhang et al. 2003] or because of increased activity of PKC and Akt activation [Chalecka-Franaszek and Chuang, 1999; De Sarno et al. 2002].”
BackgroundRegulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium
De Sarno, P., Li, X., & Jope, R. S. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00215-0 · Cited by 434 · cited 3×
“…2000a; Moore et al. 2000b], as well as its effects on GSK3 [Klein and Melton, 1996; Stambolic et al. 1996; Chalecka-Franaszek and Chuang, 1999; De Sarno et al. 2002; Beaulieu et al. 2004], is thought to exert major neurotrophic effects, resulting in neuropil increases, increased…”
BackgroundO'Brien, W. T., Harper, A. D., Jové, F., Woodgett, J. R., Maretto, S., Piccolo, S., & Klein, P. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4753-03.2004 · Cited by 415 · cited 1×
“…is emerging from animal studies, which link GSK3 and manic- or depressive-like behaviours [Beaulieu et al. 2004; Gould et al. 2004; Kaidanovich-Beilin et al. 2004; O’Brien et al. 2004, Prickaerts et al. 2006; Polter et al. 2010], potentially due to lithium-induced Akt activation [Pan et al. 2011].”
BackgroundMoore, G. J., Bebchuk, J. M., Hasanat, K., Chen, G., Seraji-Bozorgzad, N., Wilds, I. B., Faulk, M. W., Koch, S., Glitz, D. A., Jolkovsky, L., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00252-3 · Cited by 401 · cited 4×
“The regional specificity of these findings makes it unlikely that these findings are due to the osmotic effects of lithium; instead, the neurotrophic effect of lithium seems a more viable explanation [Moore et al. 2000b; Sassi et al. 2002; Bearden et al. 2007; Monkul et al. 2007].”
BackgroundInfluentialGlycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs
Gould, T. D., & Manji, H. K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300731 · Cited by 375 · cited 5×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialA β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior
Beaulieu, J.-M., Marion, S., Rodriguiz, R. M., Medvedev, I. O., Sotnikova, T. D., Ghisi, V., Wetsel, W. C., Lefkowitz, R. J., Gainetdinov, R. R., & Caron, M. G. (2008) · Cell · doi:10.1016/j.cell.2007.11.041 · Cited by 362
Yasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358 · cited 3×
“Several of the previously described mechanisms, independently or synergistically, may be protective of brain cell functioning [Chiu and Chuang 2010]: inhibition of glutamatergic excitotoxicity via NMDA receptor-mediated calcium influx; inhibition of autophagy, including in the presence of the insult of β-amyloid [Alva…”
BackgroundManji, H. K., Moore, G. J., & Chen, G. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00979-3 · Cited by 352 · cited 2×
“Notably, lithium’s ability to robustly increase expression of the cytoprotective protein B-cell lymphoma/leukaemia 2 (bcl-2) [Chen et al. 1999; Manji et al. 2000a; Moore et al. 2000b], as well as its effects on GSK3 [Klein and Melton, 1996; Stambolic et al. 1996; Chalecka-Franaszek and Chuang,…”
BackgroundA rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin
Sarkar, S., Krishna, G., Imarisio, S., Saiki, S., O'Kane, C. J., & Rubinsztein, D. C. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm294 · Cited by 349 · cited 2×
“2005], whilst inhibition of GSK-3β by higher doses of lithium (Ki ≈ 2 mM) suppresses autophagy, by varying activation of the negative regulator mTOR [Sarkar et al. 2008; Chiu and Chuang, 2010].”
BackgroundInfluentialPrickaerts, J., Moechars, D., Cryns, K., Lenaerts, I., van Craenendonck, H., Goris, I., Daneels, G., Bouwknecht, J. A., & Steckler, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5216-05.2006 · Cited by 341 · cited 1×
“…is emerging from animal studies, which link GSK3 and manic- or depressive-like behaviours [Beaulieu et al. 2004; Gould et al. 2004; Kaidanovich-Beilin et al. 2004; O’Brien et al. 2004, Prickaerts et al. 2006; Polter et al. 2010], potentially due to lithium-induced Akt activation [Pan et al. 2011].”
BackgroundLithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons
Muñoz-Montaño, J. R., Moreno, F. J., Avila, J., & Dı́az-Nido, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00688-1 · Cited by 322 · cited 6×
“2004] decreases the phosphorylation of tau protein and of MAP-1B [Hong et al. 1997; Munoz-Montano et al. 1997; Lovestone et al. 1999; Engel et al. 2006; Leroy et al. 2010], reducing their ability to bind to microtubules, leading to the promotion of microtubule assembly [Hong et al.”
BackgroundInfluentialGould, T. D., Einat, H., Bhat, R., & Manji, H. K. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004535 · Cited by 314 · cited 2×
“Evidence of its therapeutic relevance is emerging from animal studies, which link GSK3 and manic- or depressive-like behaviours [Beaulieu et al. 2004; Gould et al. 2004; Kaidanovich-Beilin et al. 2004; O’Brien et al. 2004, Prickaerts et al. 2006; Polter et al. 2010], potentially due to lithium-induced Akt activation […”
BackgroundReduced Brain Inositol in Lithium-treated Rats
ALLISON, J. H., & STEWART, M. A. (1971) · Nature New Biology · doi:10.1038/newbio233267a0 · Cited by 310 · cited 3×
“…phosphates involved in inositol phosphate metabolism, including the intracellular enzymes IMPase and inositol polyphosphatase 1-phosphatase (IPP 1) [Allison and Stewart, 1971; Berridge et al. 1989; Phiel and Klein, 2001]; this inhibition leads to inositol depletion, a consequential reduction in…”
BackgroundResultIn Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300439 · Cited by 300 · cited 1×
“In addition, lithium’s usage is limited by its narrow therapeutic window and significant range of adverse side effects [Livingstone and Rampes, 2006; McKnight et al. 2012]; better understanding its mechanism of action may allow the development of more effective and more tolerable pharmacological…”
BackgroundRobust Quantification of Polymerase Chain Reactions Using Global Fitting
Carr, A. C., & Moore, S. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037640 · Cited by 297
Greater Cortical Gray Matter Density in Lithium-Treated Patients with Bipolar Disorder
Bearden, C. E., Thompson, P. M., Dalwani, M., Hayashi, K. M., Lee, A. D., Nicoletti, M., Trakhtenbroit, M., Glahn, D. C., Brambilla, P., Sassi, R. B., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.027 · Cited by 289 · cited 2×
“The regional specificity of these findings makes it unlikely that these findings are due to the osmotic effects of lithium; instead, the neurotrophic effect of lithium seems a more viable explanation [Moore et al. 2000b; Sassi et al. 2002; Bearden et al. 2007; Monkul et al. 2007].”
BackgroundGlycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Kockeritz, L., Doble, B., Patel, S., & Woodgett, J. (2006) · Current Drug Targets · doi:10.2174/1389450110607011377 · Cited by 284 · cited 2×
“2006] and is primarily regulated through inhibition of its activity via a combination of factors [Kaidanovick-Beilin and Woodgett, 2011], including phosphorylation, intracellular localisation and sequestration by binding proteins [Doble and Woodgett, 2003; Jope and Johnson, 2004; Kockeritz et al. 2006].”
BackgroundA Chaperone-Dependent GSK3β Transitional Intermediate Mediates Activation-Loop Autophosphorylation
Lochhead, P. A., Kinstrie, R., Sibbet, G., Rawjee, T., Morrice, N., & Cleghon, V. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.10.009 · Cited by 283 · cited 10×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialKaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., & Eldar-Finkelman, H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.008 · Cited by 276 · cited 2×
“…relevance is emerging from animal studies, which link GSK3 and manic- or depressive-like behaviours [Beaulieu et al. 2004; Gould et al. 2004; Kaidanovich-Beilin et al. 2004; O’Brien et al. 2004, Prickaerts et al. 2006; Polter et al. 2010], potentially due to lithium-induced Akt activation…”
BackgroundManji, H. K., Moore, G. J., & Chen, G. (2000) · PubMed · Cited by 272
Inhibition of GSK3 by lithium, from single molecules to signaling networks
Freland, L., & Beaulieu, J.-M. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00014 · Cited by 269 · cited 6×
“com 167 auto-activation, providing at least two additional mechanisms by which lithium’s existing therapeutic effects can be strengthened [Freland and Beaulieu, 2012].”
BackgroundInfluentialIncreased gray matter volume in lithium-treated bipolar disorder patients
Sassi, R. B., Nicoletti, M., Brambilla, P., Mallinger, A. G., Frank, E., Kupfer, D. J., Keshavan, M. S., & Soares, J. C. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00615-8 · Cited by 263 · cited 4×
“The regional specificity of these findings makes it unlikely that these findings are due to the osmotic effects of lithium; instead, the neurotrophic effect of lithium seems a more viable explanation [Moore et al. 2000b; Sassi et al. 2002; Bearden et al. 2007; Monkul et al. 2007].”
BackgroundInfluentialManji, H. K., & Lenox, R. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00235-8 · Cited by 241 · cited 1×
“Chronic lithium treatment downregulates the expression of the PKC substrate ‘myristoylated alanine-rich C kinase substrate’ (MARCKS), a protein associated with long-term neuroplastic events in the developing and adult brain [Manji and Lenox, 1999].”
BackgroundSutherland, C., & Cohen, P. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80112-6 · Cited by 238 · cited 8×
“Although composed of two isoforms, GSK-3α and GSK-3β, which 166 http://tpp.sagepub.com generally have similar biochemical properties [Gould and Manji, 2005], much of the research in this area has focused on GSK-3β [Phiel and Klein, 2001].”
BackgroundInfluentialZhu, L.-Q., Wang, S.-H., Liu, D., Yin, Y.-Y., Tian, Q., Wang, X.-C., Wang, Q., Chen, J.-G., & Wang, J.-Z. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3321-07.2007 · Cited by 234 · cited 1×
“Notably, activation of GSK3 has been shown to inhibit the development of glutamatergic N-methyl-D-aspartate (NMDA) receptor-dependent long-term potentiation (LTP), causing changes to neuronal synaptic plasticity and contributing to learning and memory deficits [Zhu et al. 2007].”
BackgroundLithium for maintenance treatment of mood disorders
Burgess, S. S., Geddes, J., Hawton, K. K., Taylor, M. J., Townsend, E., Jamison, K., & Goodwin, G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003013 · Cited by 232
Chiu, C.-T., & Chuang, D.-M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.006 · Cited by 229 · cited 16×
“GSK3 is a critical downstream regulator of diverse signalling pathways [Zhang et al. 2003; Chiu and Chuang, 2010], and has a key role in the regulation of a number of cell functions, including insulin receptor signalling, the specification of cell fates during embryonic development, immunity and…”
BackgroundInfluentialPolter, A., Beurel, E., Yang, S., Garner, R., Song, L., Miller, C. A., Sweatt, J. D., McMahon, L., Bartolucci, A. A., Li, X., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.43 · Cited by 225 · cited 2×
“…is emerging from animal studies, which link GSK3 and manic- or depressive-like behaviours [Beaulieu et al. 2004; Gould et al. 2004; Kaidanovich-Beilin et al. 2004; O’Brien et al. 2004, Prickaerts et al. 2006; Polter et al. 2010], potentially due to lithium-induced Akt activation [Pan et al. 2011].”
BackgroundEngel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223
Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited
Harwood, A. J. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001618 · Cited by 209 · cited 5×
“Lithium and the phosphatidylinositol signalling pathway Over the last 40 years, a key theory regarding lithium’s pharmacodynamic actions, which has evolved from biochemical data, involves the depletion of free myo-inositol concentrations [Berridge et al. 1989; Harwood, 2005].”
BackgroundInfluentialKarege, F., Perroud, N., Burkhardt, S., Schwald, M., Ballmann, E., La Harpe, R., & Malafosse, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.036 · Cited by 208 · cited 2×
“Furthermore, abnormal GSK3 activity appears to occur in humans with depression [Karege et al. 2007; Inkster et al. 2009] and bipolar disorder [Polter et al. 2010].”
BackgroundLithium: a review of its metabolic adverse effects
Livingstone, C., & Rampes, H. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881105057515 · Cited by 184 · cited 2×
“In addition, lithium’s usage is limited by its narrow therapeutic window and significant range of adverse side effects [Livingstone and Rampes, 2006; McKnight et al. 2012]; better understanding its mechanism of action may allow the development of more effective and more tolerable pharmacological…”
BackgroundOverview of the mechanism of action of lithium in the brain: fifty-year update.
Lenox, R. H., & Hahn, C.-G. (2000) · PubMed · Cited by 181
Marmol, F. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.08.012 · Cited by 174 · cited 3×
“2005] and, more speculatively, has been considered as a possible therapeutic agent for treating chronic neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases [Marmol, 2008; Dudev and Lim, 2011].”
BackgroundResultFang, X., Yu, S., Tanyi, J. L., Lu, Y., Woodgett, J. R., & Mills, G. B. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2099-2110.2002 · Cited by 173
Lithium Impacts on the Amplitude and Period of the Molecular Circadian Clockwork
Li, J., Lu, W.-Q., Beesley, S., Loudon, A. S. I., & Meng, Q.-J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033292 · Cited by 169 · cited 2×
“…mice have been shown to display ‘manic’ behaviours that is reversed by the administration of lithium [Roybal et al. 2007] posited to be GSK3 inhibition, although lithium has also been noted to affect the free firing rate of mouse suprachiasmatic nucleus neurons [Abe et al. 2000; Li et al. 2012].”
BackgroundLithium lengthens the circadian period of individual suprachiasmatic nucleus neurons
Abe, M., Herzog, E. D., & Block, G. D. (2000) · NeuroReport · doi:10.1097/00001756-200009280-00042 · Cited by 169 · cited 2×
“…mice have been shown to display ‘manic’ behaviours that is reversed by the administration of lithium [Roybal et al. 2007] posited to be GSK3 inhibition, although lithium has also been noted to affect the free firing rate of mouse suprachiasmatic nucleus neurons [Abe et al. 2000; Li et al. 2012].”
BackgroundLovestone, S., Davis, D. R., Webster, M.-T., Kaech, S., Brion, J., Matus, A. I., & Anderton, B. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00183-8 · Cited by 166 · cited 4×
“Inhibition of GSK3 by lithium [Klein and Melton, 1996; Stambolic et al. 1996; ChaleckaFranaszek and Chuang, 1999; De Sarno et al. 2002; Beaulieu et al. 2004] decreases the phosphorylation of tau protein and of MAP-1B [Hong et al. 1997; Munoz-Montano et al. 1997; Lovestone et al. 1999; Engel et al. 2006; Leroy et al. 2…”
BackgroundInfluentialOpposite effects of suicidality and lithium on gray matter volumes in bipolar depression
Benedetti, F., Radaelli, D., Poletti, S., Locatelli, C., Falini, A., Colombo, C., & Smeraldi, E. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.006 · Cited by 165 · cited 1×
“…or partly reverse the grey-matter deficits seen in bipolar patients [Sassi et al. 2002] has also been linked to specific therapeutic effects, including its effects on suicidality, potentially through impacting on goal directed behaviour and affecting cognitive distortions [Benedetti et al. 2011].”
BackgroundPKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers
Manji, H. K., & Chen, G. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001018 · Cited by 165 · cited 4×
“…is only the first stage of action, initiating a cascade of secondary changes in the PKC signalling pathway and gene expression [Agam et al. 2002; Manji and Chen, 2002], that are ultimately associated with lithium’s therapeutic efficacy. http://tpp.sagepub.com 165 Further research, and the…”
BackgroundInfluentialCleary, C., Linde, J. A. S., Hiscock, K. M., Hadas, I., Belmaker, R. H., Agam, G., Flaisher-Grinberg, S., & Einat, H. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.03.005 · Cited by 142 · cited 2×
“2010], neuroprotective [Chiu and Chuang 2010] and mood stabilisation [Cleary et al. 2008].”
BackgroundKaladchibachi, S. A., Doble, B., Anthopoulos, N., Woodgett, J. R., & Manoukian, A. S. (2007) · Journal of Circadian Rhythms · doi:10.1186/1740-3391-5-3 · Cited by 128 · cited 1×
“Animal models [Martinek et al. 2001; Mohawk et al. 2009; Kaladchibachi et al. 2007] have demonstrated that lithium lengthens the circadian period in a dose-dependent manner.”
BackgroundASsociation of gsk3β polymorphisms with brain structural changes in major depressive disorder
Inkster, B., Nichols, T. E., Saemann, P. G., Auer, D. P., Holsboer, F., Muglia, P., & Matthews, P. M. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.70 · Cited by 127 · cited 2×
“Furthermore, abnormal GSK3 activity appears to occur in humans with depression [Karege et al. 2007; Inkster et al. 2009] and bipolar disorder [Polter et al. 2010].”
BackgroundLithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease
Mendes, C. T., Mury, F. B., Moreira, E. D. S., Alberto, F., Forlenza, O. V., Dias‐Neto, E., & Gattaz, W. F. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0828-5 · Cited by 126 · cited 1×
“Furthermore, recent findings have shown that GSK-3β transcription can be decreased by lithium treatment in vitro and in vivo [Mendes et al. 2009], highlighting the wide-ranging effects of lithium on GSK3 regulation.”
BackgroundMonkul, E. S., Matsuo, K., Nicoletti, M., Dierschke, N. A., Hatch, J. P., Dalwani, M. S., Brambilla, P., Caetano, S. C., Sassi, R. B., Mallinger, A. G., et al. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.074 · Cited by 126 · cited 3×
“…found increased dorsolateral prefrontal cortex and cingulate grey matter volume and increased white matter volume in healthy subjects following lithium administration [Monkul et al. 2007], potentially highlighting the different generalised effects of lithium in healthy and diseased brains.”
BackgroundThe neurotrophic and neuroprotective effects of psychotropic agents
Hunsberger, J., Austin, D. R., Henter, I. D., & Chen, G. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/jhunsberger · Cited by 123 · cited 2×
“Accumulating evidence suggests that the therapeutic effects of mood stabilisers are realised through neurotrophic/neuroprotective effects, offering an explanation for the clinical efficacy of lithium in mood disorders and implicating lithium as a potential therapeutic agent in the treatment of neurodegenerative diseas…”
Bipolar disorder and myo‐inositol: a review of the magnetic resonance spectroscopy findings
Silverstone, P. H., McGrath, B. M., & Kim, H. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2004.00174.x · Cited by 122 · cited 5×
“This notion is further supported by the fact that lithium is an uncompetitive inhibitor of IMPase [Berridge and Irvine, 1989], thus the level of inhibition increases at high substrate concentrations; since myo-inositol levels are higher in bipolar patients [Silverstone et al. 2005], the level of inhibition is increase…”
BackgroundInfluentialReduced suicide risk during lithium maintenance treatment.
Tondo, L., & Baldessarini, R. J. (2000) · PubMed · Cited by 118
Alvarez, G., Muñoz‐Montaño, J. R., Satrústegui, J., Avila, J., Bogónez, E., & Díaz‐Nido, J. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01150.x · Cited by 116 · cited 2×
“Several of the previously described mechanisms, independently or synergistically, may be protective of brain cell functioning [Chiu and Chuang 2010]: inhibition of glutamatergic excitotoxicity via NMDA receptor-mediated calcium influx; inhibition of autophagy, including in the presence of the insult of β-amyloid [Alva…”
BackgroundAKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice
Pan, J. Q., Lewis, M. C., Ketterman, J. K., Clore, E. L., Riley, M. M., Richards, K. R., Berry-Scott, E., Liu, X., Wagner, F. F., Holson, E. B., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.24 · Cited by 115 · cited 1×
“…is emerging from animal studies, which link GSK3 and manic- or depressive-like behaviours [Beaulieu et al. 2004; Gould et al. 2004; Kaidanovich-Beilin et al. 2004; O’Brien et al. 2004, Prickaerts et al. 2006; Polter et al. 2010], potentially due to lithium-induced Akt activation [Pan et al. 2011].”
BackgroundJones, R. M., Arlidge, J., Gillham, R., Reagu, S., van den Bree, M., & Taylor, P. J. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.083030 · Cited by 113 · cited 1×
“In addition, it has been noted to effect aggressiveness [Jones et al. 2011], reduce suicide rates in affective disorders [Tondo and Baldessarini, 2000; Cipriani et al. 2005] and, more speculatively, has been considered as a possible therapeutic agent for treating chronic neurodegenerative diseases…”
BackgroundIntracellular pathways underlying the effects of lithium
Pasquali, L., Busceti, C. L., Fulceri, F., Paparelli, A., & Fornai, F. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833da5da · Cited by 112 · cited 9×
“…inositol monophosphatase (IMPase) within the phosphatidylinositol (PI) signalling pathway [Berridge et al. 1989] and the protein kinase glycogen synthase kinase 3β (GSK-3β) [Ryves and Harwood, 2001], although therapeutic effects may be due to further downstream effects [Pasquali et al. 2010].”
BackgroundInfluentialLithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A
Mora, A., Sabio, G., Risco, A. M., Cuenda, A., Alonso, J. C., Soler, G., & Centeno, F. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00282-0 · Cited by 111 · cited 2×
“…of N-terminal serine residues of GSK3 [Chiu and Chuang, 2010; Pasquali et al. 2010], either due to inhibition of the protein phosphatases [Mora et al. 2002; Zhang et al. 2003] or because of increased activity of PKC and Akt activation [Chalecka-Franaszek and Chuang, 1999; De Sarno et al.…”
BackgroundO’Brien, W. T., Huang, J., Buccafusca, R., Garskof, J., Valvezan, A. J., Berry, G. T., & Klein, P. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45194 · Cited by 109 · cited 2×
“2003] and by stabilising the Akt;βArr2;PP2A signalling complex, leading to Akt dephosphorylation [O’Brien et al. 2011].”
Background(2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45138 · Cited by 108 · cited 2×
“Alteration of intracellular calcium homeostasis has been identified in mood disorders, and downstream regulation of calcium signalling following lithium [Sourial-Bassillious et al. 2009] offers another potential therapeutic mechanism [Bauer et al. 2003a; Wasserman et al. 2004; Perova et al. 2008].”
BackgroundLeroy, K., Ando, K., Héraud, C., Yilmaz, Z., Authelet, M., Boeynaems, J.-M., Buée, L., De Decker, R., & Brion, J.-P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1276 · Cited by 103
Chemical and kinetic mechanism of the inositol monophosphatase reaction and its inhibition by Li+
Leech, A., Baker, G. R., Shute, J. K., COHEN, M. A., & Gani, D. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17707.x · Cited by 91 · cited 1×
“As a result, lithium is able to compete with magnesium and successfully bind to metal-binding sites in several magnesiumdependent enzymes including GSK3 [Ryves and Harwood, 2001] and IMPase [Leech et al. 1993; Haimovich et al. 2012].”
BackgroundChronic Lithium Treatment Attenuates Intracellular Calcium Mobilization
Wasserman, M. J., Corson, T. W., Sibony, D., Cooke, R. G., Parikh, S. V., Pennefather, P., Li, P. P., & Warsh, J. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300400 · Cited by 90
Lithium augmentation therapy in refractory depression?Update 2002
Bauer, M., Forsthoff, A., Baethge, C., Adli, M., Berghöfer, A., D�pfmer, S., & Bschor, T. (2003) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-003-0430-9 · Cited by 86 · cited 2×
“Alteration of intracellular calcium homeostasis has been identified in mood disorders, and downstream regulation of calcium signalling following lithium [Sourial-Bassillious et al. 2009] offers another potential therapeutic mechanism [Bauer et al. 2003a; Wasserman et al. 2004; Perova et al. 2008].”
BackgroundCompetition between Li + and Mg 2+ in Metalloproteins. Implications for Lithium Therapy
Dudev, T., & Lim, C. (2011) · Journal of the American Chemical Society · doi:10.1021/ja201985s · Cited by 86 · cited 8×
“Magnesium: the common cofactor One key hypothesis for the inhibitory effects of lithium on enzymatic targets such as GSK3 and IMPase postulates the competition between lithium and the native enzymatic cofactor magnesium for metal-binding sites [Dudev and Lim, 2011].”
BackgroundInfluentialLithium Upregulates Vascular Endothelial Growth Factor in Brain Endothelial Cells and Astrocytes
Guo, S., Arai, K., Stins, M. F., Chuang, D.-M., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.524504 · Cited by 85 · cited 3×
“2009] and vascular endothelial growth factor (VEGF) [Guo et al. 2009].”
BackgroundLenox, R. H., & Watson, D. G. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.2.309 · Cited by 81 · cited 1×
“Cytoskeletal growth stabilisation and plasticity appear to lead to stabilisation of aberrant neuronal activity, a conceptually attractive target for a mood-stabilising drug [Lenox and Watson, 1994].”
BackgroundSystematic overview of lithium treatment in acute mania
Poolsup, Po, L. W., & de Oliveira (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00278.x · Cited by 76 · cited 2×
“Lithium is primarily used in the recovery of bipolar affective disorder, with evidence supporting its role in both acute mania [Gershon and Soares, 1997; Soares and Gershon, 1998, 2000; Bowden, 2000; Poolsup et al. 2000; Shafti, 2010] and prophylactic treatment [Soares and Gershon, 1998, 2000; Burgess et al.”
BackgroundCurrent Therapeutic Profile of Lithium
Gershon, S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130020004 · Cited by 70 · cited 2×
“Lithium is primarily used in the recovery of bipolar affective disorder, with evidence supporting its role in both acute mania [Gershon and Soares, 1997; Soares and Gershon, 1998, 2000; Bowden, 2000; Poolsup et al. 2000; Shafti, 2010] and prophylactic treatment [Soares and Gershon, 1998, 2000; Burgess et al.”
BackgroundGlutamate-mediated calcium signaling: A potential target for lithium action
Sourial-Bassillious, N., Rydelius, P., Aperia, A. C., & Aizman, O. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.04.013 · Cited by 64 · cited 5×
“The effects of lithium on the PI signalling pathway, for example [Berridge et al. 1989], leads to a reduction in levels of IP3, an important stimulator for intracellular calcium (Ca2+) levels [Sourial-Bassillious et al. 2009].”
BackgroundInfluentialHyperactive intracellular calcium dynamics in B lymphoblasts from patients with bipolar I disorder
Perova, T., Wasserman, M. J., Li, P. P., & Warsh, J. J. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007973 · Cited by 63 · cited 2×
“Alteration of intracellular calcium homeostasis has been identified in mood disorders, and downstream regulation of calcium signalling following lithium [Sourial-Bassillious et al. 2009] offers another potential therapeutic mechanism [Bauer et al. 2003a; Wasserman et al. 2004; Perova et al. 2008].”
BackgroundEfficacy of lithium in mania and maintenance therapy of bipolar disorder.
Bowden, C. L. (2000) · PubMed · Cited by 56
The Lithium Ion: A Foundation for Psychopharmacological Specificity
Soares, J., & Gershon, S. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00022-0 · Cited by 56 · cited 2×
“…is primarily used in the recovery of bipolar affective disorder, with evidence supporting its role in both acute mania [Gershon and Soares, 1997; Soares and Gershon, 1998, 2000; Bowden, 2000; Poolsup et al. 2000; Shafti, 2010] and prophylactic treatment [Soares and Gershon, 1998, 2000; Burgess…”
BackgroundGarc�a-P�rez, J., Avila, J., & D�az-Nido, J. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19980515)52:4<445::aid-jnr8>3.0.co;2-9 · Cited by 50 · cited 2×
“…al. 2006; Leroy et al. 2010], reducing their ability to bind to microtubules, leading to the promotion of microtubule assembly [Hong et al. 1997; Munoz-Montano et al. 1997] and increased axonal spreading and increases in the growth cone area and perimeter [Garcia-Perez et al. 1998], respectively.”
BackgroundMore good news about the magic ion: lithium may prevent dementia
Young, A. H. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.082875 · Cited by 49 · cited 2×
“Considerable interest has been shown in putative neuroprotective actions of lithium, particularly with regards to dementing illnesses, although the epidemiological evidence remains challengeable [Young, 2011].”
BackgroundMyo‐inositol‐1‐phosphate (MIP) synthase: a possible new target for antibipolar drugs
Agam, G., Shamir, A., Shaltiel, G., & Greenberg, M. L. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.4.s1.2.x · Cited by 45 · cited 2×
“The mechanism by which lithium exerts its effects on the PI signalling pathway is still unclear, and it remains possible, for example, that a decrease in intracellular myoinositol is only the first stage of action, initiating a cascade of secondary changes in the PKC signalling pathway and gene expression [Agam et al.…”
BackgroundHaimovich, A., Eliav, U., & Goldbourt, A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211794x · Cited by 45 · cited 8×
“Yet, despite lithium’s extensive clinical applications and its ability to provide potentially lifesaving treatment to patients [Nemeroff, 2000; Jope, 2003], the exact mechanisms by which it exerts its therapeutic effects remain incompletely understood [Phiel and Klein, 2001; Gould and Manji, 2005; Haimovich et al. 201…”
BackgroundInfluentialCrespo‐Biel, N., Camins, A., Pallàs, M., & Canudas, A. M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.012 · Cited by 38 · cited 2×
“…release from the ER, with effects on neuronal functioning [Harwood, 2005]; this includes reduction in the activity of the calcium-dependent protein calpain and calpain-mediated activation of pro-apoptotic cyclin-dependent kinase 5 (Cdk5), leading to reduced cellular death [Crespo-Biel et al. 2009].”
BackgroundLithium in unipolar depression and the prevention of suicide.
Coppen, A. J. (2000) · PubMed · Cited by 36
Ferrie, L., H. Young, A., & McQuade, R. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006243 · Cited by 36 · cited 3×
“Animal models have demonstrated that clinically relevant doses of lithium lead to neurobiological changes in DA function, with lithium administration in rodents over a 1-month period affecting presynaptic DA function and attenuating potassium-evoked DA release [Ferrie et al. 2006].”
BackgroundInfluentialKennedy, N., & Paykel, E. S. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00192-7 · Cited by 27 · cited 2×
“It is also efficacious in the treatment of unipolar depression [Coppen, 2000], particularly as augmentation therapy in severe refractory depression [Bauer et al. 2003b; Kennedy and Paykel, 2004], and bipolar depression [Lloyd et al. 2011].”
BackgroundOlanzapine vs. lithium in management of acute mania
Shafti, S. S. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.08.013 · Cited by 26 · cited 2×
“Lithium is primarily used in the recovery of bipolar affective disorder, with evidence supporting its role in both acute mania [Gershon and Soares, 1997; Soares and Gershon, 1998, 2000; Bowden, 2000; Poolsup et al. 2000; Shafti, 2010] and prophylactic treatment [Soares and Gershon, 1998, 2000; Burgess et al.”
BackgroundInositol Monophosphatase Activity in Brain and Lymphocyte-Derived Ceii Lines of Bipolar Patients
Shaltiel, G., Shamir, A., Nemanov, L., Yaroslavsky, Y., Nemets, B., Ebstein, R. P., Belmaker, R. H., & Agam, G. (2001) · The World Journal of Biological Psychiatry · doi:10.3109/15622970109027499 · Cited by 23 · cited 1×
“Shaltiel and colleagues, for example, found reduced IMPase activity in lymphocyte-derived cell lines of bipolar patients [Shaltiel et al. 2001].”
BackgroundBipolar depression: clinically missed, pharmacologically mismanaged
Lloyd, L. C., Giaroli, G., Taylor, D. M., & Tracy, D. K. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311420752 · Cited by 21 · cited 2×
“2003b; Kennedy and Paykel, 2004], and bipolar depression [Lloyd et al. 2011].”
BackgroundSelf-citationMohawk, J. A., Miranda‐Anaya, M., Tataroğlu, Ö., & Menaker, M. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a8f43 · Cited by 18 · cited 1×
“Animal models [Martinek et al. 2001; Mohawk et al. 2009; Kaladchibachi et al. 2007] have demonstrated that lithium lengthens the circadian period in a dose-dependent manner.”
BackgroundThe psychopharmacologic specificity of the lithium ion: origins and trajectory.
Soares, J. C., & Gershon, S. (2000) · PubMed · Cited by 17
Physicians Postgraduate Press in the 21st Century
(2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0101 · Cited by 9
Association Between Premenstrual Syndrome and Depression
Soares, C. N., & Cohen, L. S. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0914a · Cited by 9
Introduction. Norepinephrine: neurotransmitter for the millennium.
Nemeroff, C. B. (2000) · PubMed · Cited by 3
Introduction: Fifty Years of Lithium Use in the Treatment of Bipolar Disorder
Nemeroff, C. B. (2000) · The Journal of Clinical Psychiatry · Cited by 1
Research works printed but not linked: 7
- Bowden C., 2000, J Clin Psychiatry, 61, 35
- Burgess S., 2001, Cochrane Database Syst Rev, CD003013
- Coppen A., 2000, J Clin Psychiatry, 61, 52
- Lenox R., 2000, J Clin Psychiatry, 61, 5
- Li J., 2012, Plos One, 7, 8
- Manji H., 2000, J Clin Psychiatry, 61, 82
- Tondo L., 2000, J Clin Psychiatry, 61, 97
Cited by
Cutillo, C. M., Sharma, K. R., Foschini, L., Kundu, S., Mackintosh, M., Mandl, K. D., MI in Healthcare Workshop Working Group, Beck, T., Collier, E., Colvis, C., et al. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-0254-2 · Cited by 337
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
“Diacylglycerate remains bound to the membrane and leads downstream activation of protein kinase C and increases the release of calcium from intracellular stores (Conn and Sanders-Bush, 1984; Brown and Tracy, 2013).”
BackgroundLithium: A review of pharmacology, clinical uses, and toxicity
Oruch, R., Elderbi, M. A., Khattab, H. A., Pryme, I. F., & Lund, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.042 · Cited by 221
Vijay, G. V., Zhao, N., Den Hollander, P., Toneff, M. J., Joseph, R., Pietila, M., Taube, J. H., Sarkar, T. R., Ramirez-Pena, E., Werden, S. J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1125-0 · Cited by 163
“The lithium ion competes with magnesium ions that are required for kinase activity [37, 38].”
BackgroundPharmacological Treatments for Patients with Treatment-Resistant Depression
Ruberto, V. L., Jha, M. K., & Murrough, J. W. (2020) · Pharmaceuticals · doi:10.3390/ph13060116 · Cited by 147
Metadata
- Authors
- Brown, K. M., & Tracy, D. K.
- Affiliations
- King's College London (GB)
- Oxleas NHS Foundation Trust (GB)
- ORCID
- Tracy, Derek K.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-12-21
- Volume
- 3
- Issue
- 3
- Pages
- 163-176
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC3805456
- OpenAlex
- W2131991500
- Cited by
- 140
- References
- 124
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 9 · 2019: 10 · 2018: 10 · 2017: 9 · 2016: 9 · 2015: 18 · 2014: 8 · 2013: 1
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- lithium, pharmacodynamics, glycogen synthase kinase-3, inositol monophosphatase, magnesium cofactor, mood disorders, neurodegenerative diseases, enzyme inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.